Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

MRNA

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

MRNA

AI Research Report

Powered by Claude

Ready to analyze MRNA

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

A-
Stonvex Quant Grade
81.7/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
A+
97 / 100

Today's volume vs prior session average.

Volatility
A+
95 / 100

Absolute daily price move vs peers.

News Flow
A+
94 / 100

24h article count relative to the universe.

Sentiment
A
86 / 100

AI-classified polarity of recent news.

Dollar Flow
F
13 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
A+
95 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
LLY
Eli Lilly
$810.50
+2.30%
NVO
Novo Nordisk
—
—
BNTX
BioNTech
—
—
REGN
Regeneron
—
—
VRTX
Vertex Pharma
—
—
GILD
Gilead Sciences
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Moderna Inc

Moderna Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 2018-12-07
📅 Earnings in 16d (Apr 30)
NASDAQ NMS - GLOBAL MARKETMarket open
Moderna Inc
Biotechnology
$52.69
$2.01 (+3.97%)
Open
$50.75
Prev close
$50.68
Day range
$50.05 – $52.73
52W range
$22.28 – $59.55
Mkt cap
$20.02B
P/E
—
EPS
$-7.26
Beta
1.19

Factor Grades

View details →
B-
Overall score: 64/100
B-
Valuation
C
Growth
D
Profitability
A
Momentum
A
Financial Health

Fundamentals

Valuation
Market Cap
$20.02B
P/E (TTM)
—S&P avg ~22
P/S (TTM)
10.30S&P avg ~2.8
P/B
1.33S&P avg ~4.5
P/FCF
22.46S&P avg ~26
EPS (TTM)
$-7.26
Book/sh
$21.95
Cash/sh
$14.72
Profitability
Gross Margin
70.32%avg ~45%
Operating Margin
-158.13%avg ~15%
Net Margin
-145.16%avg ~12%
ROE
-30.15%avg ~18%
ROA
-22.95%avg ~7%
ROI
-29.50%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
-39.93%
Rev Growth 5Y
19.34%
EPS Growth YoY
—
EPS Growth 5Y
—
Current Ratio
—
Quick Ratio
3.08
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.19
52W High
$59.55
52W Low
$22.28
Avg Vol (10D)
5.56M
Avg Vol (3M)
10.43M
Div Yield
—
Div/sh (TTM)
—
Analyst
Sell (30)
Price Performance
5D+1.14%
MTD-0.24%
3M+49.68%
6M+84.02%
YTD+71.85%
1Y+106.86%

Analyst Consensus

Sell
Based on 30 analysts
Period: 2026-04-01
3 Buy (10%)21 Hold (70%)6 Sell (20%)
Rating Distribution
Strong Buy
0
Buy
3
Hold
21
Sell
3
Strong Sell
3
Trend
2026-04
3/21/6
2026-03
3/21/6
2026-02
3/21/6
2026-01
4/19/7
  • Yahoo·7h ago

    3 Unpopular Stocks We Approach with Caution

    Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

  • Yahoo·1d ago

    OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

    Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human healthWill assist with listeria oncology pipeline prioritization, combinations with other oncology-focused biotechnologies and tADC candidate selection for further developmentNew York, New York--(Newsfile Corp. - April 13, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in...

  • Benzinga·4d ago

    Study Showing 50% Drop In COVID ER Visits Thanks To The Vaccine Put On Hold By CDC: Report

    The CDC has reportedly delayed a report showing COVID-19 vaccine benefits, citing methodology concerns.

  • Yahoo·4d ago

    Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

    In the latest trading session, Moderna (MRNA) closed at $51.3, marking a -1.54% move from the previous day.

  • Yahoo·5d ago

    3 Mid-Cap Stocks We’re Skeptical Of

    Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

  • Benzinga·5d ago

    March Inflation Set For Biggest Jump Since June 2022 — When CPI Spikes, These Stocks Fall

    Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9% monthly CPI surge — the steepest since June 2022.

  • Yahoo·6d ago

    Moderna eyes international markets as growth driver, says Bank of America

    Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026 results, according to analysts at Bank of America. They noted that the 2025-2026 vaccine season is winding down, and the company’s litigation...

  • Yahoo·6d ago

    Moderna Flu And RSV Data Highlight Push Beyond COVID And Valuation Tension

    Moderna (NasdaqGS:MRNA) reported positive Phase 3 clinical data for its investigational influenza vaccine mRNA-1010 and RSV vaccine mRESVIA. The company is presenting these results, including late breaking sessions, at a major international infectious disease congress. Early readouts point to favorable immune responses and safety profiles across both programs. The data add clinical support for Moderna's push into seasonal respiratory vaccines beyond its existing COVID-19 product. For...

  • View all news →

Recent insider activity

View all →
  • 4PRIMARY DOCUMENT
    8d ago
  • 4PRIMARY DOCUMENT
    Mar 6
  • 4PRIMARY DOCUMENT
    Mar 6
  • 4PRIMARY DOCUMENT
    Mar 3
  • 4PRIMARY DOCUMENT
    Mar 3